If a patient has been diagnosed with type 2 diabetes and requires more help than just lifestyle changes and other drugs, Mounjaro can be a suitable choice for them at JosephCareRX
SURMOUNT-1 showed average weight loss of 21.4% at 10mg over 72 weeks

Heres how they could reshape the GLP-1 market ( Addressing Health Challenges: Tirzepatides Role in Obesity Management news.med.miami.edu ( endocrine.org ( rivasweightloss.com ( eurekalert.org ( investor.lilly.com ( Innovative Approach: How Tirzepatide Outperforms Traditional Weight Loss Methods eurekalert.org ( Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine | Eli Lilly and Company ( finance.yahoo.com ( Lillys tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks | Eli Lilly and Company ( primehealthmd.com ( Medical Supervision: Ensuring Safe and Effective Use of Tirzepatide onlinelibrary.wiley.com ( pmc.ncbi.nlm.nih.gov ( fda.gov ( Tirzepatide Once Weekly for the Treatment of Obesity | NEJM ( Outcomes from a Medical Weight Loss Program: Primary Care Clinics Versus Weight Loss Clinics ( Comprehensive Benefits: Why Tirzepatide is the Top Choice for Weight Loss Tirzepatide Enhances Weight Loss with Sustained Treatment but Discontinuation Leads to Weight Regain ( uvahealth.com ( healio.com ( rivasweightloss.com ( pharmaceutical-journal.com (

This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access $189.00 per year only $15.75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
Significant results are usually measured over a six-month to one-year period, as the body adjusts to its new metabolic baseline
The new trial design itself may mark a turning point